- Home
- CYN vs CVM Comparison
CYN vs CVM Comparison
Compare CYN & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYN | CVM |
|---|---|---|
| Founded | 2013 | 1983 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 19.3M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CYN | CVM |
|---|---|---|
| Price | $1.64 | $1.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 257.8K | ★ 268.7K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $368,138.00 | $264,033.00 |
| Revenue This Year | $3,359.28 | N/A |
| Revenue Next Year | $347.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.33 | $1.44 |
| 52 Week High | $41.54 | $13.48 |
Technical Indicators
Market Signals| Indicator | CYN | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 26.10 |
| Support Level | $1.49 | N/A |
| Resistance Level | $1.76 | $4.84 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 33.59 | 0.39 |
Price Performance
Historical ComparisonAbout CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.